Interpace to Present Data at the ATA Annual Meeting
October 29 2019 - 6:55AM
Interpace (IDXG) announced today that it will be presenting new
data on the performance of its molecular thyroid products at the
upcoming 89th Annual Meeting of the American Thyroid Association
(ATA), being held October 30th to November 3rd, 2019 in Chicago,
IL. The ATA meeting is one of the largest gatherings of
endocrinologists, ENT’s, surgeons and other providers who focus on
the diagnosis and treatment of thyroid cancer.
Interpace will be presenting three separate
posters focused on the performance of the company’s molecular tests
for indeterminate thyroid nodules, ThyGeNEXT® and ThyraMIR®, and
are titled:
- “Estimation of malignancy association for mutations and
fusions, detected by NGS, by incorporating the results of microRNA
expression profiling assay for a large set of clinical
specimens”
- “Molecular analysis of non-Diagnostic (B-I) thyroid nodule
cytology samples using combined mutational detection and microRNA
classifier test”
- “Molecular diagnosis of medullary thyroid carcinoma by NGS
mutation detection and microRNA expression profiling”
Together
these posters underline the clinical utility of ThyGeNEXT® and
ThyraMIR® in assessing the risk of thyroid nodules with
indeterminate cytology results progressing to cancer. They also
highlight progress made by the Company to provide quality
diagnostic information for the detection of aggressive forms of
thyroid cancer.
Jack Stover, CEO of Interpace, stated, “We are
pleased that our data has been accepted for presentation in this
prestigious forum and look forward to sharing our work with such an
established group of attendees.” Mr. Stover continued, “The
acceptance of our data supports our belief that our molecular
products continue to add value to physicians and patients at risk
of thyroid cancer.”
About Thyroid Nodules, ThyGeNEXT® and
ThyraMIR® Testing
According to the American Thyroid Association,
approximately 20% of the 525,000 thyroid fine needle aspirations
(FNAs) performed on an annual basis in the U.S. are indeterminate
for malignancy based on standard cytological evaluation, and thus
are candidates for ThyGeNEXT® and ThyraMIR®.
ThyGeNEXT® and ThyraMIR® reflex testing yields
high predictive value in determining the presence and absence of
cancer in thyroid nodules. The combination of both tests can
improve risk stratification and surgical decision-making when
standard cytopathology does not provide a clear diagnosis.
ThyGeNEXT® utilizes state-of-the-art
next-generation sequencing (NGS) to identify more than 100 genetic
alterations associated with papillary and follicular thyroid
carcinomas, the two most common forms of thyroid cancer, as well as
Meduallary Thyroid Carcinoma. ThyraMIR® is the first microRNA gene
expression classifier. MicroRNAs are small, non-coding RNAs that
bind to messenger RNA and regulate expression of genes involved in
human cancers, including every subtype of thyroid cancer. ThyraMIR®
measures the expression of 10 microRNAs. Both ThyGeNEXT® and
ThyraMIR® are covered by both Medicare and Commercial insurers,
with more than 280 million patients covered.
About Interpace
Interpace is a leader in enabling personalized
medicine, offering specialized services along the therapeutic value
chain from early diagnosis and prognostic planning to targeted
therapeutic applications.
Interpace’s Diagnostic Business is a fully
integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
for the diagnosis of thyroid cancer from thyroid nodules utilizing
a next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX® that differentiates lung cancer of
primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s
Esophagus, is currently in a clinical evaluation program whereby we
gather information from physicians using BarreGEN® to assist us in
positioning the product for full launch, partnering and potentially
supporting reimbursement with payers.
Interpace’s Biopharma Business provides
pharmacogenomics testing, genotyping, biorepository and other
customized services to the pharmaceutical and biotech industries.
The Biopharma Business also advances personalized medicine by
partnering with pharmaceutical, academic, and technology leaders to
effectively integrate pharmacogenomics into their drug development
and clinical trial programs with the goals of delivering safer,
more effective drugs to market more quickly, and improving patient
care.
For more information, please visit Interpace’s
website at www.interpacediagnostics.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to the fact that there is no assurance the acquisition of
the BioPharma business of Cancer Genetics, Inc. will be
successfully integrated with the Company, or that the potential
benefits of the acquisition, including future revenues, will be
successfully realized. Additionally, all forward-looking statements
are subject to the “Risk Factors” detailed from time to time in the
Company's most recent Annual Report on Form 10-K, Current Reports
on Form 8-K and Quarterly Reports on Form 10-Q. Because of these
and other risks, uncertainties and assumptions, undue reliance
should not be placed on these forward-looking statements. In
addition, these statements speak only as of the date of this press
release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:Investor Relations - Edison GroupJoseph
Green(646) 653-7030jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024